RxDoctor Payments Data

Alyssa Reznor, PA

Surgical · Pittsburgh, PANPI 1982398368

Payments from drug & device makers

$1,033in general payments, 2019–2025

Across 21 payments — averaging $49.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cequr Corporation$430
  • AbbVie$137
  • Amgen$128
  • GSK$114
  • Novartis$46
  • Heartflow, Inc.$40
  • plus $137 from 6 others

What the payments were for

  • Food & beverage$1,033100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,033 in reported general payments places this provider in the 70th percentile of 626 surgical providers in Pennsylvania.

See all surgical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$34,046
Medicare patients
170
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$117,186
JardianceEmpagliflozin58$89,668
EliquisApixaban65$71,265
MounjaroTirzepatide28$36,380
Tresiba Flextouch U-200Insulin Degludec17$27,517
XareltoRivaroxaban26$26,913
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$23,798
TrulicityDulaglutide11$15,841
FarxigaDapagliflozin Propanediol14$14,768
Breo ElliptaFluticasone/Vilanterol21$8,302
Dexlansoprazole DrDexlansoprazole13$3,428
Levothyroxine Sodium292$3,167
Atorvastatin Calcium307$2,788
Albuterol Sulfate HfaAlbuterol Sulfate84$2,087
Rosuvastatin Calcium155$1,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$89,66858 claims
PfizerEliquis$14$71,26565 claims
Lilly USA, LLCMounjaro, Trulicity$35$52,22139 claims
GSKTrelegy Ellipta, Breo Ellipta$114$32,10056 claims
AbbVieSynthroid$137$1,50844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 626 surgical providers in Pennsylvania.

Other surgical in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →